Aptose Biosciences, Inc.2024财年第三财季实现净利润-6.95百万美元，同比增加39.30%

市场透视11-16

11月16日，Aptose Biosciences, Inc.（APTO.US）公布财报，公告显示公司2024财年第三财季净利润为-6.95百万美元，同比增加39.30%；其中营业收入为0.00美元，每股基本收益为-0.37美元。从资产负债表来看，Aptose Biosciences, Inc.（APTO.US）总负债20.06百万美元，其中短期债务416000.00美元，资产负债比为0.55，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483306155?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-16 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483306155","market":"us","top_or_hot":-1,"title":"Aptose Biosciences, Inc.2024财年第三财季实现净利润-6.95百万美元，同比增加39.30%","media":"市场透视","content":"<div>\n<p>11月16日，Aptose Biosciences, Inc.（APTO.US）公布财报，公告显示公司2024财年第三财季净利润为-6.95百万美元，同比增加39.30%；其中营业收入为0.00美元，每股基本收益为-0.37美元。从资产负债表来看，Aptose Biosciences, Inc.（APTO.US）总负债20.06百万美元，其中短期债务416000.00美元，资产负债比为0.55，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000255a23b8988&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptose Biosciences, Inc.2024财年第三财季实现净利润-6.95百万美元，同比增加39.30%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptose Biosciences, Inc.2024财年第三财季实现净利润-6.95百万美元，同比增加39.30%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000255a23b8988&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月16日，Aptose Biosciences, Inc.（APTO.US）公布财报，公告显示公司2024财年第三财季净利润为-6.95百万美元，同比增加39.30%；其中营业收入为0.00美元，每股基本收益为-0.37美元。从资产负债表来看，Aptose Biosciences, Inc.（APTO.US）总负债20.06百万美元，其中短期债务416000.00美元，资产负债比为0.55，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000255a23b8988&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APTO","symbol_name":"Aptose Biosciences Inc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000255a23b8988&s=b","article_id":"2483306155","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000255a23b8988&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483306155","pubTimestamp":1731686433,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月16日，Aptose Biosciences, Inc.公布财报，公告显示公司2024财年第三财季净利润为-6.95百万美元，同比增加39.30%；其中营业收入为0.00美元，每股基本收益为-0.37美元。从资产负债表来看，Aptose Biosciences, Inc.总负债20.06百万美元，其中短期债务416000.00美元，资产负债比为0.55，流动比率为1.05。机构评级：截至2024年11月16日，当前有1家机构对Aptose Biosciences, Inc.目标价做出预测，其中目标均价为7.00美元，其中最低目标价为7.00美元，最高目标价为7.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"APTO":"Aptose Biosciences Inc"},"translate_title":"Aptose Biosciences, Inc. achieved net profit of-US $6.95 million in the third fiscal quarter of fiscal 2024, a year-on-year increase of 39.30%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APTO":0.9},"content_text":"11月16日，Aptose Biosciences, Inc.（APTO.US）公布财报，公告显示公司2024财年第三财季净利润为-6.95百万美元，同比增加39.30%；其中营业收入为0.00美元，每股基本收益为-0.37美元。从资产负债表来看，Aptose Biosciences, Inc.（APTO.US）总负债20.06百万美元，其中短期债务416000.00美元，资产负债比为0.55，流动比率为1.05。机构评级：截至2024年11月16日，当前有1家机构对Aptose Biosciences, Inc.目标价做出预测，其中目标均价为7.00美元，其中最低目标价为7.00美元，最高目标价为7.00美元。公司简介：Aptose Biosciences Inc 是一家临床阶段的生物技术公司，致力于发现和开发个性化疗法，以满足肿瘤学中未满足的医疗需求。 该公司的小分子癌症治疗管道包括旨在提供单一药物疗效和增强其他抗癌疗法和方案疗效而没有重叠毒性的产品。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483306155"}